Pacific Biosciences of California, Inc. Proceeds from Sale of Available-for-sale Securities
Pacific Biosciences of California, Inc. (PACB) reported Proceeds from Sale of Available-for-sale Securities of $212.73 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2021-11-05
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2021-09-30 was $178.18M.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2021-06-30 was $29.96M.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2021-03-31 was $4.60M.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2019-12-31 was $0.00.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for fiscal 2020 was $1.40M, a 6.67% decline from fiscal 2019.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for fiscal 2019 was $1.50M, a 38.57% decline from fiscal 2018.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for fiscal 2018 was $2.44M, a 65.66% decline from fiscal 2017.
- Pacific Biosciences of California, Inc. proceeds from sale of available-for-sale securities for fiscal 2017 was $7.11M, a 69.46% decline from fiscal 2016.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2021-09-30 | $178.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $208.14M derived: sum of 2 quarters · filed 2021-11-05 | $212.73M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $29.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $34.56M 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | $4.60M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $1.40M 10-K · filed 2021-02-26 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $1.50M 10-K · filed 2021-02-26 | ||
| 2019-09-30 | $1.50M 10-Q · filed 2020-11-03 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $0.00 derived: sum of 3 quarters · filed 2021-02-26 | $2.44M 10-K · filed 2021-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $2.44M 10-Q · filed 2019-11-07 | $5.89M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.44M 10-Q · filed 2019-08-06 | $5.89M derived: sum of 3 quarters · filed 2020-02-28 | $5.89M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $2.44M 10-Q · filed 2019-05-03 | $5.89M derived: sum of 2 quarters · filed 2020-02-28 | $5.89M derived: sum of 3 quarters · filed 2020-02-28 | $5.89M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $3.45M derived: sum of 2 quarters · filed 2020-02-28 | $3.45M derived: sum of 3 quarters · filed 2020-02-28 | $7.11M 10-K · filed 2020-02-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2018-11-05 | $3.66M 10-Q · filed 2018-11-05 | $7.12M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $3.66M 10-Q · filed 2018-08-03 | $7.12M derived: sum of 3 quarters · filed 2019-02-26 | $13.61M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $3.66M 10-Q · filed 2018-05-02 | $7.12M derived: sum of 2 quarters · filed 2019-02-26 | $13.61M derived: sum of 3 quarters · filed 2019-02-26 | $22.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $9.95M derived: sum of 2 quarters · filed 2019-02-26 | $18.34M derived: sum of 3 quarters · filed 2019-02-26 | $23.29M 10-K · filed 2019-02-26 |
| 2016-09-30 | $6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $14.88M derived: sum of 2 quarters · filed 2017-11-02 | $19.83M 10-Q · filed 2017-11-02 | $19.83M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $8.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $13.33M 10-Q · filed 2017-08-02 | $13.33M derived: sum of 3 quarters · filed 2018-02-26 | $14.83M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $4.95M 10-Q · filed 2017-05-05 | $4.95M derived: sum of 2 quarters · filed 2018-02-26 | $6.45M derived: sum of 3 quarters · filed 2018-02-26 | $6.45M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $1.50M derived: sum of 2 quarters · filed 2018-02-26 | $1.50M derived: sum of 3 quarters · filed 2018-02-26 | $8.32M 10-K · filed 2018-02-26 |
| 2015-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.50M derived: sum of 2 quarters · filed 2016-11-04 | $8.32M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $6.82M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $6.82M 10-Q · filed 2016-05-05 | |||
| 2013-12-31 | $100.00K 10-K · filed 2016-03-11 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.04M derived: sum of 2 quarters · filed 2015-03-12 | $4.40M derived: sum of 3 quarters · filed 2015-03-12 | $7.90M 10-K · filed 2015-03-12 |
| 2012-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $4.40M derived: sum of 2 quarters · filed 2013-11-12 | $7.90M 10-Q · filed 2013-11-12 | $7.90M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $4.86M 10-Q · filed 2013-08-09 | $4.86M derived: sum of 3 quarters · filed 2014-03-14 | $4.86M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $3.50M 10-Q · filed 2013-05-10 | $3.50M derived: sum of 2 quarters · filed 2014-03-14 | $3.50M derived: sum of 3 quarters · filed 2014-03-14 | -$14.00M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $0.00 derived: sum of 2 quarters · filed 2014-03-14 | -$17.50M derived: sum of 3 quarters · filed 2014-03-14 | $36.52M 10-K · filed 2014-03-14 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$17.50M derived: sum of 2 quarters · filed 2012-11-01 | $36.52M 10-Q · filed 2012-11-01 | |
| 2011-06-30 | -$17.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $36.52M 10-Q · filed 2012-08-07 | ||
| 2011-03-31 | $54.02M 10-Q · filed 2012-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |